Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
Dashti A, Waller C, Mavigner M, Schoof N, Bar KJ, Shaw GM, Vanderford TH, Liang S, Lifson JD, Dunham RM, Ferrari G, Tuyishime M, Lam CK, Nordstrom JL, Margolis DM, Silvestri G, Chahroudi A. Dashti A, et al. Among authors: lam ck. J Virol. 2020 Oct 14;94(21):e00793-20. doi: 10.1128/JVI.00793-20. Print 2020 Oct 14. J Virol. 2020. PMID: 32817214 Free PMC article.
Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.
Pollara J, Edwards RW, Jha S, Lam CK, Liu L, Diedrich G, Nordstrom JL, Huffman T, Pickeral JA, Denny TN, Permar SR, Ferrari G. Pollara J, et al. Among authors: lam ck. Front Immunol. 2020 Apr 21;11:713. doi: 10.3389/fimmu.2020.00713. eCollection 2020. Front Immunol. 2020. PMID: 32373131 Free PMC article.
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.
Liu L, Lam CK, Long V, Widjaja L, Yang Y, Li H, Jin L, Burke S, Gorlatov S, Brown J, Alderson R, Lewis MD, Nordstrom JL, Koenig S, Moore PA, Johnson S, Bonvini E. Liu L, et al. Among authors: lam ck. Clin Cancer Res. 2017 Mar 15;23(6):1506-1518. doi: 10.1158/1078-0432.CCR-16-0666. Epub 2016 Sep 23. Clin Cancer Res. 2017. PMID: 27663593
Notes from the Field: Supply Interruptions of First- and Second-Line Oral Drugs to Treat Tuberculosis During the Previous 12 Months - California, January-March, 2023.
Nabity SA, Agraz-Lara R, Bravo A, Benjamin R, Fong V, Lam CK, Keh C, Mase S, Flood J. Nabity SA, et al. Among authors: lam ck. MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1390-1391. doi: 10.15585/mmwr.mm725253a2. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38175801 Free article. No abstract available.
Tachycardia-induced metabolic rewiring as a driver of contractile dysfunction.
Tu C, Caudal A, Liu Y, Gorgodze N, Zhang H, Lam CK, Dai Y, Zhang A, Wnorowski A, Wu MA, Yang H, Abilez OJ, Lyu X, Narayan SM, Mestroni L, Taylor MRG, Recchia FA, Wu JC. Tu C, et al. Among authors: lam ck. Nat Biomed Eng. 2024 Apr;8(4):479-494. doi: 10.1038/s41551-023-01134-x. Epub 2023 Nov 27. Nat Biomed Eng. 2024. PMID: 38012305 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
270 results